A Trial to Evaluate Para-Aortic Lymphadenectomy for Gastric Cancer
This study has been completed.
Sponsor:
Japan Clinical Oncology Group
Collaborator:
Ministry of Health, Labour and Welfare, Japan
Information provided by:
Japan Clinical Oncology Group
ClinicalTrials.gov Identifier:
NCT00149279
First received: September 7, 2005
Last updated: May 31, 2007
Last verified: May 2007
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | September 7, 2005 | ||||
| Last Updated Date | May 31, 2007 | ||||
| Start Date ICMJE | July 1995 | ||||
| Primary Completion Date | Not Provided | ||||
| Current Primary Outcome Measures ICMJE |
overall survival | ||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||
| Change History | Complete list of historical versions of study NCT00149279 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE |
|
||||
| Original Secondary Outcome Measures ICMJE | Same as current | ||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | A Trial to Evaluate Para-Aortic Lymphadenectomy for Gastric Cancer | ||||
| Official Title ICMJE | Randomized Controlled Trial to Evaluate Para-Aortic Lymphadenectomy for Gastric Cancer (JCOG9501) | ||||
| Brief Summary | To evaluate the survival benefit of para-aortic lymphadenectomy in potentially curative gastrectomy |
||||
| Detailed Description | Radical gastrectomy with regional lymphadenectomy is the only curative treatment option for gastric cancer. The extent of lymphadenectomy, however, is controversial. The two European randomized trials only reported an increase in operative morbidity and mortality, but failed to show survival benefit, in the D2 lymphadenectomy group. We conducted a randomized controlled trial to compare the Japanese standard D2 and D2 + para-aortic nodal dissection. |
||||
| Study Type ICMJE | Interventional | ||||
| Study Phase | Phase 3 | ||||
| Study Design ICMJE | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
||||
| Condition ICMJE | Gastric Neoplasm | ||||
| Intervention ICMJE |
|
||||
| Study Arm (s) | Not Provided | ||||
| Publications * |
|
||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Completed | ||||
| Enrollment ICMJE | 520 | ||||
| Completion Date | April 2006 | ||||
| Primary Completion Date | Not Provided | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria: - Preoperatively,
Exclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | up to 75 Years | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Location Countries ICMJE | Japan | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT00149279 | ||||
| Other Study ID Numbers ICMJE | JCOG9501, C000000121 | ||||
| Has Data Monitoring Committee | Yes | ||||
| Responsible Party | Not Provided | ||||
| Study Sponsor ICMJE | Japan Clinical Oncology Group | ||||
| Collaborators ICMJE | Ministry of Health, Labour and Welfare, Japan | ||||
| Investigators ICMJE |
|
||||
| Information Provided By | Japan Clinical Oncology Group | ||||
| Verification Date | May 2007 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||